Leviticus Cardio Achieves Successful Transcutaneous Coplanar Energy Transfer in Chronic Animal Model
The company will be at the "EUMS2015" meeting in Paris, December 3-5 to discuss the results of this pre-clinical chronic animal study.
Nov 16, 2015, 08:23 ET
PETAH TIKVA, Israel, Nov. 16, 2015 /PRNewswire/ -- Leviticus Cardio (www.Leviticus-cardio.com) announces positive achievement of preclinical study evaluating their transcutaneous Coplanar Energy Transfer (CET) system in a chronic animal model. In the study, conducted at the Catholic University of Leuven, Belgium under the supervision of Professor Bart Meyns, MD, Ph.D. the device was well tolerated in animals for 28 days. Additionally, the experience indicates stable and consistent energy transfer, suggesting the capability for discharge and re-charge cycles of its implanted battery powered control unit to be examined in further studies.
"This encouraging data builds on prior preclinical data presented at ISHLT 2015 demonstrating the CET system," states Assoc. Professor Ivan Netuka, MD, Ph.D., Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic. "The successful implant of the wireless Coplanar Energy Transfer (CET) system developed by Leviticus Cardio in a chronic ovine model [70Kg] providing power to the implanted HVAD® system [Heartware International Inc. Framingham, Mass.] has achieved its target endpoint of 28 days, demonstrating that the CET system is an efficient tool delivering both stable and consistent energy transfer.
We implanted the system to power the HVAD® on the 14th October 2015 to determine the long-term stability in a chronic animal model. The results of the study indicate:
- Daily 6-9 hours discharge and 4 hour re-charge cycles, achieved using normal HVAD power of 5 Watts at 2400 RPMs.
- Eleven hours full discharge characteristic with time to alarm (10 hours) and time between alarm and LVAD stop (24 min).
- 28 days system stability.
"Importantly, the data reinforces our belief that the CET system has the potential to provide substantial Quality of Life improvement and infection reduction for patients treated with a ventricular assist device," comments MUDr. Jiří Malý, MD, Ph.D, of IKEM, Prague.
Michael Zilbershlag, BSc, MBA, CEO of Leviticus Cardio, comments, "This is a very important step towards the feasibility study and a significant milestone for the technology. We are pleased with these results, which will enable us to move forward." Also announced today, is the achievement of ISO13485 certification, "a critical step in our ability to manufacture our product, enabling us to progress towards our feasibility and CE Mark study" states Mr. Zilbershlag.
About Leviticus Cardio
Leviticus Cardio is a medical device company dedicated to improve the clinical outcome for patients implanted with a left ventricular assist device (LVAD) for impaired cardiac function. Major investors include The Trendlines Group, Israel's foremost seed- and early-stage investment group, a consortium of acclaimed cardiovascular physicians, private investors and Israel's Office of the Chief Scientist (OCS) in the Ministry of Economy.
Contact: Michael Zilbershlag, CEO. T: +972.50.880.7135
CALENDAR INFO
EUMS 2015 (European Mechanical Circulatory Support) meeting at Eurosites Georges V, Paris, France December 2nd-5th, 2015
VAD update session
Media relations
Keren Ofek-Machluf
keren@ofirpr.co.il
+972 (4) 9535030
Photo - http://photos.prnewswire.com/prnh/20150413/198049
SOURCE Leviticus Cardio
Share this article